BioXCel reported some new healthy volunteer data that it’s touting as positive.
The biotech said in a press release Tuesday that its experimental BXCL501 therapy as an adjunct for major depressive disorder proved safe and tolerable in a Phase Ib multiple-ascending dose trial, results that allow...
